These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 7486896)

  • 1. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila.
    Baltch AL; Smith RP; Ritz W
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1661-6. PubMed ID: 7486896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of levofloxacin, erythromycin or rifampicin pretreatment on growth of Legionella pneumophila in human monocytes.
    Smith RP; Baltch AL; Franke M; Hioe W; Ritz W; Michelsen P
    J Antimicrob Chemother; 1997 Nov; 40(5):673-8. PubMed ID: 9421315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila.
    Baltch AL; Smith RP; Franke MA; Michelsen PB
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3153-6. PubMed ID: 9835507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative activity of ciprofloxacin, ofloxacin, levofloxacin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells.
    Stout JE; Arnold B; Yu VL
    Diagn Microbiol Infect Dis; 1998 Jan; 30(1):37-43. PubMed ID: 9488830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia.
    Edelstein PH; Edelstein MA; Lehr KH; Ren J
    J Antimicrob Chemother; 1996 Jan; 37(1):117-26. PubMed ID: 8647752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic susceptibility of Legionella pneumophila strains isolated in England and Wales 2007-17.
    Wilson RE; Hill RLR; Chalker VJ; Mentasti M; Ready D
    J Antimicrob Chemother; 2018 Oct; 73(10):2757-2761. PubMed ID: 30053025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of resistance to erythromycin, rifampicin and ciprofloxacin in 98 clinical isolates of Legionella pneumophila.
    Onody C; Matsiota-Bernard P; Nauciel C
    J Antimicrob Chemother; 1997 Jun; 39(6):815-6. PubMed ID: 9222053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.
    Gómez-Lus R; Adrián F; del Campo R; Gómez-Lus P; Sánchez S; García C; Rubio MC
    Int J Antimicrob Agents; 2001 Jul; 18(1):49-54. PubMed ID: 11463526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insufficient evidence of synergistic effect of levofloxacin and rifampin against Legionella pneumophila.
    van Ogtrop ML
    Antimicrob Agents Chemother; 1996 Feb; 40(2):524-5. PubMed ID: 8834916
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapeutic efficacy of levofloxacin against a model of replicable Legionella pneumophila lung infection in DBA/2 mice].
    Kashimoto Y; Kurosaka Y; Karibe Y; Uoyama S; Fujikawa K; Namba K; Otani T; Yamaguchi K
    Jpn J Antibiot; 2009 Oct; 62(5):452-9. PubMed ID: 20055122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.
    Dubois J; St-Pierre C
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():41-6. PubMed ID: 10824031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of clarithromycin alone and in combination with ciprofloxacin or levofloxacin against Legionella spp.: enhanced effect by the addition of the metabolite 14-hydroxy clarithromycin.
    Martin SJ; Pendland SL; Chen C; Schreckenberger PC; Danziger LH
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):167-71. PubMed ID: 9401809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.
    Edelstein PH; Edelstein MA
    Antimicrob Agents Chemother; 1999 Jan; 43(1):90-5. PubMed ID: 9869571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones.
    Pendland SL; Martin SJ; Chen C; Schreckenberger PC; Danziger LH
    J Clin Microbiol; 1997 Nov; 35(11):3004-6. PubMed ID: 9350781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.
    Edelstein PH; Edelstein MA; Weidenfeld J; Dorr MB
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2122-7. PubMed ID: 2073101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
    Visalli MA; Jacobs MR; Appelbaum PC
    Diagn Microbiol Infect Dis; 1997 Jul; 28(3):131-7. PubMed ID: 9294703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.
    Kang SL; Rybak MJ; McGrath BJ; Kaatz GW; Seo SM
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2702-9. PubMed ID: 7695250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimum inhibitory concentration (MIC) distribution among wild-type strains of Legionella pneumophila identifies a subpopulation with reduced susceptibility to macrolides owing to efflux pump genes.
    Vandewalle-Capo M; Massip C; Descours G; Charavit J; Chastang J; Billy PA; Boisset S; Lina G; Gilbert C; Maurin M; Jarraud S; Ginevra C
    Int J Antimicrob Agents; 2017 Nov; 50(5):684-689. PubMed ID: 28782709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species.
    Dubois J; St-Pierre C
    Diagn Microbiol Infect Dis; 1999 Apr; 33(4):261-5. PubMed ID: 10212753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of Legionella spp. to mycinamicin I and II and other macrolide antibiotics: effects of media composition and origin of organisms.
    Edelstein PH; Pasiecznik KA; Yasui VK; Meyer RD
    Antimicrob Agents Chemother; 1982 Jul; 22(1):90-3. PubMed ID: 7125633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.